Like other Sirt1 activators, RGZ administration increased Sirt6 expression and phosphorylation levels of LKB1 and AMPK, and provided protection from hepatic steatosis, suggesting that RGZ may act as a Sirt6 activator and a therapeutic strategy for NAFLD. The gene discussed is STK11; the disease is Hepatic steatosis.